Radius Health, Inc. (RDUS) Income Statement Analysis

See more : Annil Co.,Ltd (002875.SZ) Income Statement Analysis – Financial Results

Complete financial analysis of Radius Health, Inc. (RDUS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Radius Health, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.

You may be interested

PT Hetzer Medical Indonesia Tbk (MEDS.JK) Income Statement Analysis – Financial Results
Drone Delivery Canada Corp. (TAKOF) Income Statement Analysis – Financial Results
Marsons Limited (MARSONS.BO) Income Statement Analysis – Financial Results
World Wide Stone Corporation (WWST) Income Statement Analysis – Financial Results
Ochi Holdings Co., Ltd. (3166.T) Income Statement Analysis – Financial Results

Radius Health, Inc. (RDUS)

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: https://radiuspharm.com

About Radius Health, Inc.

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Revenue	2.88B	3.49B	2.76B	1.71B	173.32M	99.24M	22.11M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	2.57B	3.00B	2.31B	1.50B	16.09M	8.43M	1.33M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	307.71M	488.07M	453.19M	208.62M	157.23M	90.81M	20.78M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit Ratio	10.68%	14.00%	16.43%	12.18%	90.72%	91.51%	93.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	0.00	0.00	134.63M	159.71M	116.76M	99.91M	83.08M	107.41M	68.28M	45.72M	60.54M	54.96M	36.18M	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	144.15M	152.70M	184.16M	186.68M	77.54M	30.80M	13.67M	6.83M	9.47M	5.33M	46.78K	31.99K	0.00
Selling & Marketing	0.00	0.00	0.00	43.72M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	265.93M	263.26M	242.46M	187.88M	152.70M	184.16M	186.68M	77.54M	30.80M	13.67M	6.83M	9.47M	5.33M	46.78K	31.99K	0.00
Other Expenses	-5.56M	-692.00K	-455.00K	-124.00K	0.00	10.80M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	265.93M	263.26M	242.46M	187.88M	269.46M	294.88M	269.75M	184.95M	99.08M	59.39M	67.37M	64.43M	41.51M	46.78K	31.99K	0.00
Cost & Expenses	2.84B	3.26B	2.55B	1.69B	285.55M	303.30M	271.09M	184.95M	99.08M	59.39M	67.37M	64.43M	41.51M	46.78K	31.99K	0.00
Interest Income	0.00	0.00	75.00K	1.40M	3.93M	5.62M	3.23M	2.44M	1.04M	94.00K	30.00K	64.00K	27.00K	0.00	0.00	0.00
Interest Expense	18.59M	8.54M	5.29M	8.67M	24.36M	22.45M	8.30M	0.00	1.89M	2.47M	2.44M	2.67M	758.00K	0.00	0.00	0.00
Depreciation & Amortization	89.76M	75.05M	58.60M	58.17M	2.31M	2.87M	1.95M	586.00K	176.00K	77.00K	27.00K	44.00K	40.00K	0.00	0.00	0.00
EBITDA	38.31M	226.86M	214.28M	21.45M	-106.32M	-196.02M	-243.99M	-182.22M	-99.47M	-59.94M	-58.22M	-66.42M	-41.68M	-46.78K	-31.99K	0.00
EBITDA Ratio	1.33%	6.51%	7.77%	1.25%	-61.35%	-197.52%	-1,103.42%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-3.93M	225.91M	213.73M	6.85M	-112.23M	-204.06M	-248.97M	-184.95M	-99.08M	-59.39M	-67.37M	-64.43M	-41.51M	-46.78K	-31.99K	0.00
Operating Income Ratio	-0.14%	6.48%	7.75%	0.40%	-64.75%	-205.63%	-1,125.96%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	-51.27M	401.00K	2.54M	-14.01M	-20.76M	-17.27M	-5.26M	2.14M	-2.45M	-3.09M	6.68M	-4.70M	-236.00K	0.00	0.00	0.00
Income Before Tax	-28.08M	216.68M	207.99M	-1.94M	-132.99M	-221.34M	-254.24M	-182.80M	-101.53M	-62.48M	-60.69M	-69.13M	-14.63M	-46.78K	0.00	0.00
Income Before Tax Ratio	-0.97%	6.22%	7.54%	-0.11%	-76.73%	-223.03%	-1,149.77%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	-2.75M	44.60M	37.94M	166.00K	3.60M	5.18M	3.03M	2.14M	-564.00K	-619.00K	9.12M	-2.03M	522.00K	0.00	31.99K	0.00
Net Income	-25.79M	168.80M	165.11M	-4.15M	-132.99M	-221.34M	-254.24M	-182.80M	-101.53M	-62.48M	-60.69M	-69.13M	-42.48M	-46.78K	-31.99K	0.00
Net Income Ratio	-0.89%	4.84%	5.99%	-0.24%	-76.73%	-223.03%	-1,149.77%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-0.92	6.01	5.90	-0.15	-2.89	-4.88	-5.80	-4.24	-2.56	-3.53	-7.94	-7.11	-169.92	-0.02	-0.01	0.00
EPS Diluted	-0.92	5.72	5.66	-0.15	-2.89	-4.88	-5.80	-4.24	-2.56	-3.53	-7.94	-7.11	-24.59	-0.02	-0.01	0.00
Weighted Avg Shares Out	28.01M	28.08M	27.98M	27.67M	46.03M	45.36M	43.80M	43.07M	39.64M	17.70M	7.64M	9.72M	249.97K	2.50M	2.50M	2.50M
Weighted Avg Shares Out (Dil)	28.01M	29.53M	29.19M	27.67M	46.03M	45.36M	43.80M	43.07M	39.64M	17.70M	7.64M	9.72M	1.73M	2.50M	2.50M	2.50M

Radius Health to Announce Fourth Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, February 25, 2021

February 16, 2021globenewswire.com

BOSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter financial results on Thursday, February 25, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day...

Radius Health, Inc. Provides Abaloparatide Business Update

February 12, 2021globenewswire.com

BOSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a business update on the abaloparatide global business. Progress was made, and continues to be made, across the following areas.

5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty

February 12, 2021zacks.com

5 Small Drug Stocks to Buy Amid Lingering COVID-Led Uncertainty

Radius Health: Latest Pipeline Addition Is A Step In The Right Direction

January 15, 2021seekingalpha.com

Radius Health announces the acquisition of the development and commercialization rights for RAD011 from Benuvia Therapeutics. The deal economics appear favorable and should add to the top-line growth outlook while also offering diversification benefits.

Radius (RDUS) to Acquire Rights for Cannabidiol Oral Solution

January 7, 2021zacks.com

Radius (RDUS) is set to acquire the global development and commercialization rights of Benuvia Therapeutics' synthetic cannabidiol oral solution for utilization in multiple endocrine and metabolic orphan diseases.

Radius Health to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 6, 2021globenewswire.com

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Kelly Martin, President and CEO will present a virtual corporate update at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13 at 9:10 a.m. EST.

Radius (RDUS) Inks Deal for Tymlos in Canada With Paladin Labs

January 6, 2021zacks.com

Radius (RDUS) signs an agreement with Paladin Labs, wherein the latter will now be responsible for all commercial activities related to Tymlos and abaloparatide-TD in Canada.

Radius Health, Inc. Announces Acquisition of Orphan Disease Program

January 6, 2021globenewswire.com

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced a definitive agreement to acquire the global development and commercialization rights to Benuvia Therapeutics Inc.'s (“Benuvia”) synthetic cannabidiol oral solution (“RAD011”). The Company...

Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada

January 5, 2021globenewswire.com

BOSTON, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that the Company has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc (“Endo”) (NASDAQ: ENDP), to register,...

Radius Health Announces Change to its Board of Directors

January 4, 2021globenewswire.com

BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) announced today that Machelle Sanders and Dr. Andrew C. von Eschenbach have joined the Company's board of directors. Ms. Sanders and Dr. von Eschenbach will...

1 2 3 4 5 6 7 8 9 10

Source: https://incomestatements.info
Category: Stock Reports

Radius Health, Inc. (RDUS) Income Statement Analysis – Financial Results

Leave a Reply Cancel reply

Recent Posts

Categories